‘BiolineRX’ Granted Approval For Phase II Bowel Disease Trial

Drug development company BiolineRX announced that it has received approval from Israel’s Ministry of Health to commence a Phase II trial of its treatment for inflammatory bowel disease (IBD). The company reported that the Phase II trial will be an open-label study to evaluate the efficacy, safety and tolerability of the treatment, BL-7040, in up to 20 patients. The results are expected by the end of 2012. View and share